Takeda公司取消了与Amylin公司关于肥胖症研究的合作协议。该协议总价值达超过美元，并已进行三年之久。
在协议达成后，关于肥胖症的研究进展迅速，Arena的新药Belviq和Vivus的新药Qsymia都先后获得批准。同时，Amylin公司被Bristol-Myers Squibb公司收购，而BMY公司在该领域的研究更加领先。这都预示着肥胖症领域的良好前景。
Takeda公司称，今后他们将继续加强与其他公司在包括肥胖症研究在内的各领域的合作。
详细英文报道：
Takeda is writing off its three-year-old $1.1 billion pact with Amylin to develop new obesity drugs. The two companies decided to mutually terminate the pact 17 months after they scrapped a midstage study for their pramlintide/metreleptin combo.
"Having greatly benefited from the Amylin team's collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients," the companies said in a polite joint statement issued on a quiet Christmas Eve.
The biopharma world has changed considerably since Takeda agreed to pay Amylin $75 million upfront to go after the obesity market. Two new drugs, Arena's ($ARNA) Belviq and Vivus's ($VVUS) Qsymia, have since been approved, with Orexigen ($OREX) looking to catch up soon. Amylin was sold to Bristol-Myers Squibb ($BMY), which has other priorities in the pipeline. And there are other experimental drugs in the biotech pipeline whichthat offer considerable promise to dramatically lower weight, a big need in the medical field.
